University Of California Los Angeles

BARCELONA, Spain — The addition of ribociclib to fulvestrant significantly extended OS among postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, according to results of the randomized phase 3 MONALEESA-3 trial presented at European Society for Medical Oncology Congress.

Denise Aberle, MD, received International Association for the Study of Lung Cancer’s Joseph W. Cullen Prevention/Early Detection Award.

High-value care appeared associated with important patient, tumor and treatment characteristics among patients with early-stage pancreatic cancer who underwent curative resection, according to results of a retrospective study published in JAMA Surgery.

Editor’s note: This is the first in a series of articles that spotlight research efforts supported through Cancer Research Institute’s Lloyd J. Old STAR program. The program provides up to $1.25 million over a 5-year period to mid-career scientists who pursue high-risk, high-reward research in cancer immunotherapy.

Almost a third of children aged 3 years and younger who were exposed to Zika virus during their mother’s pregnancy had below-average neurological development, a recent study published in Nature Medicine suggests.

Levon — an 18-year-old with sickle cell disease — enters the clinic room with his mom, who nervously allows him to proceed alone.

Health equity witnessed a “clear lack of progress” during a recent 25-year period, researchers recently wrote in JAMA Network Open.

CHICAGO — Patients with previously treated advanced hepatocellular carcinoma demonstrated reduced risk for death and improved PFS with the addition of pembrolizumab vs. placebo to best supportive care, according to findings from the randomized phase 3 KEYNOTE-240 study presented at ASCO Annual Meeting.

CHICAGO — Pembrolizumab appeared to substantially increase OS compared with historical control rates among patients with advanced non-small cell lung cancer, according to 5-year data from the phase 1b KEYNOTE-001 study presented at ASCO Annual Meeting.

CHICAGO — Premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer derived a significant survival benefit from the addition of ribociclib to endocrine therapy, according to the most recent OS results from the randomized phase 3 MONALEESA-7 study presented at ASCO Annual Meeting.